Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 2020 AAAAI Annual Meeting
The accepted abstract is listed below and now available at jacionline.org.
Presentation Title: PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients With Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy
Session Title: Late Breaking Oral Abstract Session
Session Date & Time: Saturday, March 14, 2020 from 2:00 – 3:15 p.m. ET
Presenter: Cem Akin, M.D., Ph.D.
Abstract ID: 12615
Conference Call Information
Blueprint Medicines will host a live webcast on
About Blueprint Medicines
Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have one precision therapy approved by the
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-updated-data-from-phase-2-pioneer-trial-of-avapritinib-in-patients-with-indolent-systemic-mastocytosis-at-2020-aaaai-annual-meeting-301009943.html
SOURCE
Investor Relations Contact, Kristin Hodous, 617-714-6674, ir@blueprintmedicines.com; Media Relations Contact, Andrew Law, 617-844-8205, media@blueprintmedicines.com